CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company makes progress toward broad patient access Atrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026 Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational priorities Company to host investor call and webcast at 8:30am ET todayMONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided...

Revenues Grew 20%, GAAP Operating Income Increased to $4.4 Million, Adjusted EBITDA Doubled to $15.1 MillionReiterates Guidance for 2026 PETAH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the first quarter, ended March 31, 2026. First Quarter 2026 Financial HighlightsRevenues of $110.5 million, compared with $92 million in Q1 2025; GAAP operating income of $4.4 million, compared with GAAP operating loss of $2.7 million in Q1 2025; Non-GAAP operating income of $12.5 million, compared with $5.2 million in Q1 2025; GAAP net income of $5.2 million, or $0.07 per diluted share, compared with GAAP net loss of $6 million, or $0.11 loss per diluted share, in Q1 2025; Non-GAAP...

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051 Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026 $46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026,...

–Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— –Company to host conference call and webcast today at 8:00 a.m. ET— MIAMI, FL, May 13, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 second quarter ended March 31, 2026, and provided a corporate update. “We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients...

Announced with Cerberus the formation of Frontier Power USA, a stand-alone purpose-built entity to develop, finance, and operate LDES projects to accelerate energy storage deployments  Entered into a 2 GWh firm capacity reservation agreement with Frontier Power USA $57.0 million in quarterly revenue with the last two quarters surpassing full year 2025 revenue Achieved record quarterly production performance for shipments, battery output, and bipolar manufacturing Completed Factory Acceptance Testing for its second battery line with installation and power-on at the Thorn Hill facility underway; initial production is on schedule and expected to begin by the end of the second quarter Surpassed 6.0 GWh of discharged energy from Eos technology; DawnOS™ demonstrating consistent operating performance and improved round trip efficiency Expanded...

A total of 2,088 hotels, or 232,298 hotel rooms, in operation as of March 31, 2026. Net revenues for the first quarter of 2026 increased by 47.5% year-over-year to RMB2,811 million (US$408 million). Net income for the first quarter of 2026 increased by 90.3% year-over-year to RMB463 million (US$67 million). Adjusted net income (non-GAAP)1 for the first quarter of 2026 increased by 42.0% year-over-year to RMB490 million (US$71 million). EBITDA (non-GAAP)2 for the first quarter of 2026 increased by 85.2% year-over-year to RMB689 million (US$100 million). Adjusted EBITDA (non-GAAP)3 for the first quarter of 2026 increased by 51.1% year-over-year to RMB716 million (US$104 million).SHANGHAI, China, May 13, 2026 (GLOBE NEWSWIRE) — Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading lifestyle group...

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – – Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 – – Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 – – First subject dosed in Phase 1 trial of ZB021 (oral IL-17AA/AF inhibitor); initial clinical data expected by year-end – – Orelabrutinib global Phase 3 PriMroSe trial in patients with PPMS and global Phase 3 Monarch trial in patients with naSPMS ongoing – – Completed public offerings and entered into debt financing; cash runway extended into 2029 – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma”...

MONACO, May 13, 2026 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (“Costamare Bulkers” or the “Company”) (NYSE: CMDB) today reported unaudited financial results for the first quarter ended March 31, 2026 (“Q1 2026”). Financial Highlights1 and Operational Updates I. PROFITABILITY – LIQUIDITY – DEBTQ1 2026 Net Income of $9.9 million ($0.41 earnings per share). Q1 2026 Adjusted Net Income2 of $12.4 million ($0.51 earnings per share). Q1 2026 liquidity of $353.3 million3. Cash4 exceeding Debt5 by $127.2 million as of the end of Q1 2026.II. FLEET RENEWAL  Vessel AcquisitionConclusion of the purchase of the 2018-built, 60,297 DWT capacity dry bulk vessel, Astros (ex. Koushun)6.Long-term Charter-in AgreementsDelivery of the newbuild, 81,800 DWT capacity dry bulk vessel, Hermes Century:Minimum tenor...

GMV Increased 40% YoY and Revenue Increased 33% YoY Adjusted EBITDA Margins Expanded 330 Basis Points YoY to 19.9% Raising FY 2026 Outlook Across All Guidance Metrics PETAH-TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE) the platform powering global direct-to-consumer e-commerce, today reported financial results for the first quarter of 2026. “The first quarter showed strong momentum, fueled by volume growth from both existing merchants and recently launched brands, translating into GMV growth of 40% and an increase in our Adjusted EBITDA margin to nearly 20%, once again demonstrating the operating leverage inherent in our model,” said Amir Schlachet, Founder and CEO of Global-e. “We believe these results and our consistent execution validate our market leadership position. We...

WeRide Inc. Announces First Quarter 2026 Unaudited Financial Results NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsTotal revenue was RMB114.1 million (US$16.5 million), representing an increase of 57.6% year over year.Product revenue was RMB20.5 million (US$3.0 million), representing an increase of 115.8% year over year, primarily attributable to increased revenue from robotaxi and other L4 vehicle sales. Service revenue was RMB93.7 million (US$13.6 million), representing an increase of 49.0% year over year.Gross profit was RMB39.6 million (US$5.7 million), representing an increase...